A SIMPLE, SAFE, RELIABLE
Innoventric develops a percutaneous, easy-to-deploy,
functional tricuspid valve replacement that utilizes cross-caval anchoring
and a unique multi-valve design, for long-lasting blood flow regulation.
WE DON’T ADDRESS
WE MAKE IT
Reliable cross-caval anchoring is achieved by
utilizing 2 apposing anchor points
in the tubular SVC and IVC, instead of the
complex native valve position.
BARE METAL STENT
reliable A-traumatic anchoring
and bifurcation blood inflow
for accurate positioning in
fluoroscopy based procedures
allow the required
blood inflow and
simplify device positioning
tight seal while allowing
hepatic vein inflow
Fits a wide range
skin to skin procedure
Short learning curve
Eliminates the need
for general anesthesia
Innoventric is dedicated to the development of simple yet sophisticated transcatheter solutions that significantly improve the life span and quality of life of patients with structural heart disease.
The founder and CEO of Innoventric and the inventor of the company’s technology. Amir has 15 years of experience in the medical device field, mainly in structural interventional cardiology, bringing aortic, mitral and tricuspid valve projects from concept to clinical application. Amir served in some of the most exciting structural heart projects and has a broad experience in R&D, clinical affairs, regulatory affairs and business development.
Amir holds a B.Sc. in Biomedical Engineering from Ben-Gurion University and a M.Sc in Mechanical Engineering from Tel-Aviv University.
Rafi Benary is an experienced medical device entrepreneur with over 25 years in the field of cardiovascular medical devices. Rafi has founded several leading Medical Device Startup companies over the last two decades. Rafi was the founding CEO of Ventor Technologies, which developed a unique TAVI prosthesis. Ventor was acquired by Medtronic in early 2009. In addition, Rafi was the founding CEO of Endospan Technologies – a developer of a unique aortic arch endovascular graft. Endospan entered into a distribution and optional acquisition deal with CryoLife Inc. a US based medical device manufacturer in 2019.
Rafi earned his B.E. and M.Sc. In Mechanical Engineering and Materials Science from Stony Brook University (NY).
Dr. Planer is the head of interventional cardiology at Hadassah MC. He holds extensive experience in coronaries, structural heart disease, and endovascular interventions which were acquired at leading cardiac centers such as Columbia University Medical Center and Hadassah Medical Center.
Dr. Planer has vast experience in medical device development, gathered by working on numerous medical devices and projects. Dr. Planer is an expert in maturing early-stage technology from pre-clinical work through FIH studies to proctoring physicians.
Dr. Rihal is the Chair of the Rochester Personnel Committee and former Chair of the Department of Cardiovascular Medicine (2010 – 2018).He also directed the Cardiac Catheterization Laboratory (2003- 2010). Dr. Rihal is the William S. and Ann Atherton Professor of Cardiology in honor of Dr Bob Frye and has held the academic rank of Professor of Medicine since 2004. Dr. Rihal graduated from the University of Manitoba and did his post graduate training at the Mayo Graduate School of Medicine. After three years on faculty at McMaster University, he returned to Mayo Clinic where he has been on staff for 20 years. Dr. Rihal has an MBA degree from the Carlson School of Management, University of Minnesota, and a Diploma in Strategy and Innovation form the Said School of Business, University of Oxford.
As a clinical cardiologist, Dr. Rihal specializes in interventional cardiology, with a focus on new device therapies for the minimally invasive treatment of valve and structural heart diseases.
As a physician-leader, Dr. Rihal has focused on strategy execution, developing leaders, and identifying innovative ways to deliver value in a complex and changing healthcare environment.
Dr. Rihal speaks internationally on topics relating to procedures used to treat valvular and coronary heart Disease and other innovations in cardiology. Throughout his training and career, he has received numerous awards and honors including the Proctor Harvey Outstanding Teacher Award from the American College of Cardiology, and is a nine time recipient of Teacher of the Year Award in Cardiovascular Diseases at Mayo Clinic. His research findings have been published in prestigious peer-reviewed journals such as Circulation, Journal of the American College of Cardiology, American Journal of Cardiology and JACC Cardiovascular Interventions.
Dr. Stefan Verheye, MD, PhD, has been a senior interventional cardiologist at the Antwerp Cardiovascular Center, Antwerp Belgium since 2000. He is a member of the European Association of Percutaneous Cardiovascular Interventions, a member of the Belgian Working Group on Interventional Cardiology, and has been appointed as Clinical Professor Interventional Cardiology at the University of Brussels. He serves as a member of Scientific Advisory Board of several medical device manufacturers. Dr. Verheye is the author of over 150 peer-reviewed journals (www.pubmed.com), ten book chapters, over 400 abstracts, and has led (as global principal investigator) and participated in numerous clinical (Phase I and II) and pre-clinical research studies in the field of innovative interventional cardiology (coronary artery disease, structural heart disease, heart failure). He has presented at numerous major conferences such as TCT (Transcatheter Cardiovascular Therapeutics), EuroPCR (European Percutaneous Course on Revascularization), AsiaPCR, AHA (American Heart Association), ACC (American College of Cardiology) and ESC (European Society of Cardiology) and has directed and transmitted several coronary and structural live cases to TCT, EuroPCR and ESC. He served as the medical director for V-Wave, Israel, a medical device company, developing and manufacturing inter-atrial shunt for heart failure. His entrepreneurial interests led to the co-foundation of Hilbert Paradox, NV, a start-up company encompassing a unique way of capturing and correlating digital health data, applying data- and knowledge engineering, which was later on acquired by a large CRO. He co-founded ainthoven, NV, a start-up company dedicated to on-line cardiac signal analytics by exploring the hyperspace of learning algorithms, and recently co-founded Amynas, BV a Belgian based, incorporated technology platform company specializing in nanofiber electrospinning providing anti-infective and anti-inflammatory protection for implanted devices, including CIEDs, neuro-stimulatory and orthopedic devices.
Stefan Verheye graduated from the School of Medicine at the University of Leuven in Belgium and was a resident internal medicine and cardiology both at the University of Aachen, Germany and OLV-Hospital, Aalst, Belgium. After a 2-year fellowship interventional cardiology in Aalst, Belgium, he completed a 2-year period as a research associate and visiting interventional cardiologist at the Andreas Gruentzig Cardiovascular Center at Emory University School of Medicine in Atlanta, Georgia, and served as an affiliate scientist, Division of Molecular Medicine for Yerkes Regional Primate Research Center of Emory University. He earned his PhD at the Department of Pharmaceutical Sciences of the University of Antwerp.